mTOR inhibitor

Everolimus - Temsirolimus - Temsirolimus      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

everolimus
BOLERO-2, 2011everolimus + exemestaneexemestane alone HER-2 negative HR positive nsNAI failure previously treated with endocrine therapy NCT00863655Low risk of bias conclusive
TAMRAD , 2012everolimus + tamoxifentamoxifen alone 1st line HER-2 negative HR positive postmenopausal previously treated with endocrine therapy NCT01298713Exploratory suggesting
BOLERO-3, 2014everolimus + trastuzumab + vinorelbinetrastuzumab + vinorelbine alone HER-2 positive previously treated by taxanes trastuzumab failure NCT01007942Low risk of bias conclusive
temsirolimus
HORIZON, 2013temsirolimus + letrozoleletrozole alone 1st line HR positive postmenopausal NCT00083993Low risk of bias negative

renal-cell carcinoma (advanced)

everolimus
RECORD-1, 2008everolimusplaceboNCT00410124suggesting
RECORD 3, 2014everolimussunitinibNCT00903175 -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007temsirolimusinterferon alphaNCT00065468suggesting
INTORSECT, 2014temsirolimussorafenibNCT00474786negative